2,799 results on '"Østergaard, Mikkel"'
Search Results
2. Adding ultrasound to treat-to-target shows no benefit in achieving clinical remission nor in slowing radiographic progression in rheumatoid arthritis: results from a multicenter prospective cohort
- Author
-
Sepriano, Alexandre, Ramiro, Sofia, Landewé, Robert, van der Heijde, Désirée, Ohrndorf, Sarah, FitzGerald, Olivier, Backhaus, Marina, Larché, Maggie, Homik, Joanne, Saraux, Alain, Hammer, Hilde B., Terslev, Lene, Østergaard, Mikkel, Burmester, Gerd, Combe, Bernard, Dougados, Maxime, Hitchon, Carol, Boire, Gilles, Lambert, Robert G., Dadashova, Rana, Paschke, Joel, Hutchings, Edna J., and Maksymowych, Walter P.
- Published
- 2024
- Full Text
- View/download PDF
3. Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis
- Author
-
Liu, Jianyang, Idborg, Helena, Korotkova, Marina, Lend, Kristina, van Vollenhoven, Ronald, Lampa, Jon, Rudin, Anna, Nordström, Dan, Gudbjornsson, Bjorn, Gröndal, Gerdur, Uhlig, Till, Hørslev-Petersen, Kim, Lund Hetland, Merete, Østergaard, Mikkel, Nurmohamed, Michael, and Jakobsson, Per-Johan
- Published
- 2024
- Full Text
- View/download PDF
4. Patients’ experience of a novel interdisciplinary nurse-led self-management intervention (INSELMA)—a qualitative evaluation
- Author
-
Blum, Nadine Schäffer, Esbensen, Bente Appel, Østergaard, Mikkel, Bremander, Ann, Hendricks, Oliver, Lindgren, Luise Holberg, Andersen, Lena, Jensen, Kim Vilbaek, and Primdahl, Jette
- Published
- 2024
- Full Text
- View/download PDF
5. Development of a complex Interdisciplinary Nurse-coordinated SELf-MAnagement (INSELMA) intervention for patients with inflammatory arthritis
- Author
-
Primdahl, Jette, Bremander, Ann, Hendricks, Oliver, Østergaard, Mikkel, Latocha, Kristine Marie, Andersen, Lena, Jensen, Kim Vilbaek, and Esbensen, Bente Appel
- Published
- 2024
- Full Text
- View/download PDF
6. Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment
- Author
-
Ørnbjerg, Lykke Midtbøll, Brahe, Cecilie Heegaard, Linde, Louise, Jacobsson, Lennart, Nissen, Michael J., Kristianslund, Eirik Klami, Santos, Maria José, Nordström, Dan, Rotar, Ziga, Gudbjornsson, Bjorn, Onen, Fatos, Codreanu, Catalin, Lindström, Ulf, Möller, Burkhard, Kvien, Tore K., Barcelos, Anabela, Eklund, Kari K., Tomšič, Matija, Love, Thorvardur Jon, Can, Gercek, Ionescu, Ruxandra, Loft, Anne Gitte, Mann, Herman, Pavelka, Karel, van de Sande, Marleen, van der Horst-Bruinsma, I.E., Suarez, Manuel Pombo, Sánchez-Piedra, Carlos, Macfarlane, Gary J., Iannone, Florenzo, Michelsen, Brigitte, Hyldstrup, Lise Hejl, Krogh, Niels Steen, Østergaard, Mikkel, and Hetland, Merete Lund
- Published
- 2024
- Full Text
- View/download PDF
7. Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial
- Author
-
Østergaard, Mikkel, Wu, Joseph, Fallon, Lara, Sherlock, Sarah P., Wang, Cunshan, Fleishaker, Dona, Kanik, Keith S., and Maksymowych, Walter P.
- Published
- 2023
- Full Text
- View/download PDF
8. The OMERACT whole-body MRI scoring system for inflammation in peripheral joints and entheses (WIPE) in spondyloarthritis - reference image atlas for the knee region
- Author
-
Østergaard, Mikkel, Wetterslev, Marie, Hadsbjerg, Anna EF, Maksymowych, Walter P, Eshed, Iris, Jans, Lennart, Emad, Yasser, Pedersen, Susanne J, Stoenoiu, Maria S, Bird, Paul, Foltz, Violaine, Mathew, Ashish J, Paschke, Joel, Carron, Philippe, De Marco, Gabriele, Marzo-Ortega, Helena, Møller-Bisgaard, Signe, Conaghan, Philip G, and Lambert, Robert GW
- Published
- 2024
- Full Text
- View/download PDF
9. Hip and pelvis region MRI reference image atlas for scoring inflammation in peripheral joints and entheses according to the OMERACT-MRI WIPE scoring system in patients with spondyloarthritis
- Author
-
Østergaard, Mikkel, Lambert, Robert GW, Hadsbjerg, Anna EF, Eshed, Iris, Maksymowych, Walter P, Mathew, Ashish J, Jans, Lennart, Pedersen, Susanne J, Carron, Philippe, Emad, Yasser, De Marco, Gabriele, Bird, Paul, Stoenoiu, Maria S, Foltz, Violaine, Paschke, Joel, Marzo-Ortega, Helena, Møller-Bisgaard, Signe, Conaghan, Philip G, and Wetterslev, Marie
- Published
- 2024
- Full Text
- View/download PDF
10. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice
- Author
-
Christiansen, Sara Nysom, Horskjær Rasmussen, Simon, Pons, Marion, Michelsen, Brigitte, Glintborg, Bente, Gudbjornsson, Bjorn, Grondal, Gerdur, Vencovsky, Jiri, Loft, Anne Gitte, Rotar, Ziga, Pirkmajer, Katja Perdan, Nissen, Michael J., Baranová, Jana, Macfarlane, Gary J., Jones, Gareth T., Iannone, Florenzo, Caporali, Roberto, Laas, Karin, Vorobjov, Sigrid, Giuseppe, Daniela Di, Olofsson, Tor, Provan, Sella Aarrestad, Fagerli, Karen Minde, Castrejon, Isabel, Otero-Varela, Lucia, van de Sande, Marleen, van der Horst-Bruinsma, Irene, Nordström, Dan, Kuusalo, Laura, Bernardes, Miguel, Hetland, Merete Lund, Østergaard, Mikkel, and Midtbøll Ørnbjerg, Lykke
- Published
- 2024
- Full Text
- View/download PDF
11. Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration
- Author
-
Linde, Louise, Ørnbjerg, Lykke M., Rasmussen, Simon H., Love, Thorvardur Jon, Loft, Anne Gitte, Závada, Jakub, Vencovský, Jiří, Laas, Karin, Nordstrom, Dan, Sokka-Isler, Tuulikki, Gudbjornsson, Bjorn, Gröndal, Gerdur, Iannone, Florenzo, Ramonda, Roberta, Hellamand, Pasoon, Kristianslund, Eirik K., Kvien, Tore K., Rodrigues, Ana M., Santos, Maria J., Codreanu, Catalin, Rotar, Ziga, Tomšič, Matija, Castrejon, Isabel, Díaz-Gonzáles, Federico, Di Giuseppe, Daniela, Ljung, Lotta, Nissen, Michael J., Ciurea, Adrian, Macfarlane, Gary J., Heddle, Maureen, Glintborg, Bente, Østergaard, Mikkel, and Hetland, Merete L.
- Published
- 2023
- Full Text
- View/download PDF
12. Extracellular matrix turnover biomarkers reflect pharmacodynamic effects and treatment response of adalimumab in patients with axial spondyloarthritis—results from two randomized controlled trials
- Author
-
Port, Helena, Holm Nielsen, Signe, Frederiksen, Peder, Madsen, Sofie Falkenløve, Bay-Jensen, Anne-Christine, Sørensen, Inge Juul, Jensen, Bente, Loft, Anne Gitte, Madsen, Ole Rintek, Østergaard, Mikkel, and Pedersen, Susanne Juhl
- Published
- 2023
- Full Text
- View/download PDF
13. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial
- Author
-
Rech, Juergen, Tascilar, Koray, Hagen, Melanie, Kleyer, Arnd, Manger, Bernhard, Schoenau, Verena, Hueber, Axel J, Kleinert, Stefan, Baraliakos, Xenofon, Braun, Jürgen, Kiltz, Uta, Fleck, Martin, Rubbert-Roth, Andrea, Kofler, David M, Behrens, Frank, Feuchtenberger, Martin, Zaenker, Michael, Voll, Reinhard, Venhoff, Nils, Thiel, Jens, Glaser, Cornelia, Feist, Eugen, Burmester, Gerd R, Karberg, Kirsten, Strunk, Johannes, Cañete, Juan D, Senolt, Ladislav, Filkova, Maria, Naredo, Esperanza, Largo, Raquel, Krönke, Gerhard, D'Agostino, Maria-Antonietta, Østergaard, Mikkel, and Schett, Georg
- Published
- 2024
- Full Text
- View/download PDF
14. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
- Author
-
Michelsen, Brigitte, Østergaard, Mikkel, Nissen, Michael John, Ciurea, Adrian, Möller, Burkhard, Ørnbjerg, Lykke Midtbøll, Zavada, Jakub, Glintborg, Bente, MacDonald, Alan, Laas, Karin, Nordström, Dan, Gudbjornsson, Bjorn, Iannone, Florenzo, Hellmand, Pasoon, Kvien, Tore Kristian, Rodrigues, Ana Maria, Codreanu, Catalin, Rotar, Ziga, Castrejón Fernández, Isabel, Wallman, Johan Karlsson, Vencovsky, Jiri, Loft, Anne Gitte, Heddle, Maureen, Vorobjov, Sigrid, Hokkanen, Anna-Mari, Gröndal, Gerdur, Sebastiani, Marco, van de Sande, Marleen, Kristianslund, Eirik Klami, Santos, Maria José, Mogosan, Corina, Tomsic, Matija, Díaz-González, Federico, Di Giuseppe, Daniela, and Hetland, Merete Lund
- Published
- 2023
- Full Text
- View/download PDF
15. Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study
- Author
-
Conaghan, Philip G, Nowak, Miroslawa, Du, Shuyan, Luo, Yi, Landis, Jessica, Pachai, Chahin, Fura, Aberra, Catlett, Ian M, Grasela, Dennis M, and Østergaard, Mikkel
- Published
- 2023
- Full Text
- View/download PDF
16. Improving the design of RCTs in non-radiographic axial spondyloarthritis
- Author
-
Maksymowych, Walter P., Lambert, Robert G. W., Caplan, Liron, van den Bosch, Filip E., and Østergaard, Mikkel
- Published
- 2022
- Full Text
- View/download PDF
17. Reporting Sacroiliac Joint Imaging Performed for Known or Suspected Axial Spondyloarthritis: Assessment of SpondyloArthritis International Society Recommendations
- Author
-
Diekhoff, Torsten, primary, Eshed, Iris, additional, Giraudo, Chiara, additional, Haibel, Hildrun, additional, Hermann, Kay Geert A., additional, de Hooge, Manouk, additional, Jans, Lennart, additional, Jurik, Anne Grethe, additional, Lambert, Robert G., additional, Machado, Pedro, additional, Mallinson, Michael, additional, Maksymowych, Walter P., additional, Marzo-Ortega, Helena, additional, Navarro-Compán, Victoria, additional, Østergaard, Mikkel, additional, Pedersen, Susanne J., additional, Reijnierse, Monique, additional, Rudwaleit, Martin, additional, Sommerfleck, Fernando, additional, Weber, Ulrich, additional, Baraliakos, Xenofon, additional, and Poddubnyy, Denis, additional
- Published
- 2024
- Full Text
- View/download PDF
18. ASDAS-CRP and ASDAS-ESR cut-offs for disease activity states in axial spondyloarthritis – Are they interchangeable?
- Author
-
Georgiadis, Stylianos, primary, Ørnbjerg, Lykke Midtbøll, additional, Michelsen, Brigitte, additional, Kvien, Tore K., additional, Di Giuseppe, Daniela, additional, Wallman, Johan K., additional, Závada, Jakub, additional, Provan, Sella A., additional, Kristianslund, Eirik Klami, additional, Rodrigues, Ana Maria, additional, Santos, Maria José, additional, Rotar, Žiga, additional, Pirkmajer, Katja Perdan, additional, Nordström, Dan, additional, Macfarlane, Gary J., additional, Jones, Gareth T., additional, van der Horst-Bruinsma, Irene, additional, Hellamand, Pasoon, additional, Østergaard, Mikkel, additional, and Hetland, Merete Lund, additional
- Published
- 2024
- Full Text
- View/download PDF
19. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration
- Author
-
Ørnbjerg, Lykke M., Linde, Louise, Georgiadis, Stylianos, Rasmussen, Simon H., Lindström, Ulf, Askling, Johan, Michelsen, Brigitte, Giuseppe, Daniela Di, Wallman, Johan K., Pavelka, Karel, Závada, Jakub, Nissen, Michael J., Jones, Gareth T., Relas, Heikki, Pirilä, Laura, Tomšič, Matija, Rotar, Ziga, Geirsson, Arni Jon, Gudbjornsson, Bjorn, Kristianslund, Eirik K., van sder Horst-Bruinsma, Irene, Loft, Anne Gitte, Laas, Karin, Iannone, Florenzo, Corrado, Addolorata, Ciurea, Adrian, Santos, Maria J., Santos, Helena, Codreanu, Catalin, Akkoc, Nurullah, Gunduz, Ozgul S., Glintborg, Bente, Østergaard, Mikkel, and Hetland, Merete Lund
- Published
- 2022
- Full Text
- View/download PDF
20. Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trial
- Author
-
Lend, Kristina, van Vollenhoven, Ronald F, Lampa, Jon, Lund Hetland, Merete, Haavardsholm, Espen A, Nordström, Dan, Nurmohamed, Michael, Gudbjornsson, Bjorn, Rudin, Anna, Østergaard, Mikkel, Uhlig, Till, Grondal, Gerdur, Hørslev-Petersen, Kim, Heiberg, Marte S, Sokka-Isler, Tuulikki, Koopman, Frieda A, Twisk, Jos W R, and van der Horst-Bruinsma, Irene
- Published
- 2022
- Full Text
- View/download PDF
21. Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis
- Author
-
Maksymowych, Walter P, Baraliakos, Xenofon, Lambert, Robert G, Landewé, Robert, Sandoval, David, Carlier, Hilde, Lisse, Jeffrey, Li, Xiaoqi, Hojnik, Maja, and Østergaard, Mikkel
- Published
- 2022
- Full Text
- View/download PDF
22. Extracellular matrix protein turnover markers are associated with axial spondyloarthritis—a comparison with postpartum women and other non-axial spondyloarthritis controls with or without back pain
- Author
-
Port, Helena, Nielsen, Signe Holm, Madsen, Sofie Falkenløve, Bay-Jensen, Anne-Christine, Karsdal, Morten, Seven, Sengül, Sørensen, Inge Juul, Morsel-Carlsen, Lone, Østergaard, Mikkel, and Pedersen, Susanne Juhl
- Published
- 2022
- Full Text
- View/download PDF
23. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
- Author
-
Gladman, Dafna D., Mease, Philip J., Bird, Paul, Soriano, Enrique R., Chakravarty, Soumya D., Shawi, May, Xu, Stephen, Quinn, Sean T., Gong, Cinty, Leibowitz, Evan, Poddubnyy, Denis, Tam, Lai-Shan, Helliwell, Philip S., Kavanaugh, Arthur, Deodhar, Atul, Østergaard, Mikkel, and Baraliakos, Xenofon
- Published
- 2022
- Full Text
- View/download PDF
24. Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept
- Author
-
Ahmad, Harris A., Baker, Joshua F., Conaghan, Philip G., Emery, Paul, Huizinga, Thomas W. J., Elbez, Yedid, Banerjee, Subhashis, and Østergaard, Mikkel
- Published
- 2022
- Full Text
- View/download PDF
25. Levels of extracellular matrix metabolites are associated with changes in Ankylosing Spondylitis Disease Activity Score and MRI inflammation scores in patients with axial spondyloarthritis during TNF inhibitor therapy
- Author
-
Holm Nielsen, Signe, Sun, Shu, Bay-Jensen, Anne C., Karsdal, Morten, Sørensen, Inge Juul, Weber, Ulrich, Loft, Anne Gitte, Kollerup, Gina, Thamsborg, Gorm, Madsen, Ole Rintek, Møller, Jakob, Østergaard, Mikkel, and Pedersen, Susanne Juhl
- Published
- 2022
- Full Text
- View/download PDF
26. Validation of SPARCC MRI-RETIC e-tools for increasing scoring proficiency of MRI sacroiliac joint lesions in axial spondyloarthritis
- Author
-
Maksymowych, Walter; https://orcid.org/0000-0002-1291-1755, Hadsbjerg, Anna Enevold Fløistrup E F; https://orcid.org/0000-0001-8196-4327, Østergaard, Mikkel, Micheroli, Raphael; https://orcid.org/0000-0002-8918-7304, Pedersen, Susanne Juhl; https://orcid.org/0000-0002-6500-9263, Ciurea, Adrian; https://orcid.org/0000-0002-7870-7132, Vladimirova, Nora, Nissen, Michael S; https://orcid.org/0000-0002-6326-1764, Bubova, Kristyna, Wichuk, Stephanie, de Hooge, Manouk; https://orcid.org/0000-0002-0652-9808, Mathew, Ashish J; https://orcid.org/0000-0002-2061-2042, Pintaric, Karlo, Gregová, Monika, Snoj, Ziga, Wetterslev, Marie; https://orcid.org/0000-0002-2095-9441, Gorican, Karel, Möller, Burkhard; https://orcid.org/0000-0001-8769-6167, Eshed, Iris; https://orcid.org/0000-0002-4655-9606, Paschke, Joel, Lambert, Robert Gw, Maksymowych, Walter; https://orcid.org/0000-0002-1291-1755, Hadsbjerg, Anna Enevold Fløistrup E F; https://orcid.org/0000-0001-8196-4327, Østergaard, Mikkel, Micheroli, Raphael; https://orcid.org/0000-0002-8918-7304, Pedersen, Susanne Juhl; https://orcid.org/0000-0002-6500-9263, Ciurea, Adrian; https://orcid.org/0000-0002-7870-7132, Vladimirova, Nora, Nissen, Michael S; https://orcid.org/0000-0002-6326-1764, Bubova, Kristyna, Wichuk, Stephanie, de Hooge, Manouk; https://orcid.org/0000-0002-0652-9808, Mathew, Ashish J; https://orcid.org/0000-0002-2061-2042, Pintaric, Karlo, Gregová, Monika, Snoj, Ziga, Wetterslev, Marie; https://orcid.org/0000-0002-2095-9441, Gorican, Karel, Möller, Burkhard; https://orcid.org/0000-0001-8769-6167, Eshed, Iris; https://orcid.org/0000-0002-4655-9606, Paschke, Joel, and Lambert, Robert Gw
- Abstract
BACKGROUND The Spondyloarthritis Research Consortium of Canada (SPARCC) developers have created web-based calibration modules for the SPARCC MRI sacroiliac joint (SIJ) scoring methods. We aimed to test the impact of applying these e-modules on the feasibility and reliability of these methods. METHODS The SPARCC-SIJ $_{RETIC}$ e-modules contain cases with baseline and follow-up scans and an online scoring interface. Visual real-time feedback regarding concordance/discordance of scoring with expert readers is provided by a colour-coding scheme. Reliability is assessed in real time by intraclass correlation coefficient (ICC), cases being scored until ICC targets are attained. Participating readers (n=17) from the EuroSpA Imaging project were randomised to one of two reader calibration strategies that each comprised three stages. Baseline and follow-up scans from 25 cases were scored after each stage was completed. Reliability was compared with a SPARCC developer, and the System Usability Scale (SUS) assessed feasibility. RESULTS The reliability of readers for scoring bone marrow oedema was high after the first stage of calibration, and only minor improvement was noted following the use of the inflammation module. Greater enhancement of reader reliability was evident after the use of the structural module and was most consistently evident for the scoring of erosion (ICC status/change: stage 1 (0.42/0.20) to stage 3 (0.50/0.38)) and backfill (ICC status/change: stage 1 (0.51/0.19) to stage 3 (0.69/0.41)). The feasibility of both e-modules was evident by high SUS scores. CONCLUSION The SPARCC-SIJ $_{RETIC}$ e-modules are feasible, effective knowledge transfer tools, and their use is recommended before using the SPARCC methods for clinical research and tria.
- Published
- 2024
27. Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis:a NORD-STAR study
- Author
-
Dubovyk, Violetta, Vasileiadis, Georgios K., Fatima, Tahzeeb, Zhang, Yuan, Kapetanovic, Meliha Crnkic, Kastbom, Alf, Rizk, Milad, Söderbergh, Annika, Zhao, Sizheng Steven, van Vollenhoven, Ronald F., Hetland, Merete Lund, Haavardsholm, Espen A., Nordström, Dan, Nurmohamed, Michael T., Gudbjornsson, Bjorn, Lampa, Jon, Østergaard, Mikkel, Heiberg, Marte Schrumpf, Sokka-Isler, Tuulikki, Gröndal, Gerdur, Lend, Kristina, Hørslev-Petersen, Kim, Uhlig, Till, Rudin, Anna, Maglio, Cristina, Dubovyk, Violetta, Vasileiadis, Georgios K., Fatima, Tahzeeb, Zhang, Yuan, Kapetanovic, Meliha Crnkic, Kastbom, Alf, Rizk, Milad, Söderbergh, Annika, Zhao, Sizheng Steven, van Vollenhoven, Ronald F., Hetland, Merete Lund, Haavardsholm, Espen A., Nordström, Dan, Nurmohamed, Michael T., Gudbjornsson, Bjorn, Lampa, Jon, Østergaard, Mikkel, Heiberg, Marte Schrumpf, Sokka-Isler, Tuulikki, Gröndal, Gerdur, Lend, Kristina, Hørslev-Petersen, Kim, Uhlig, Till, Rudin, Anna, and Maglio, Cristina
- Abstract
Objective This report from the NORD-STAR (Nordic Rheumatic Diseases Strategy Trials and Registries) trial aimed to determine if obesity is associated with response to conventional and biological antirheumatic treatment in early rheumatoid arthritis (RA). Methods This report included 793 participants with untreated early RA from the randomised, longitudinal NORD-STAR trial, all of whom had their body mass index (BMI) assessed at baseline. Obesity was defined as BMI ≥30 kg/m2. All participants were randomised 1:1:1:1 to one of four treatment arms: active conventional treatment, certolizumab-pegol, abatacept and tocilizumab. Clinical and laboratory measurements were performed at baseline and at 8, 12, 24 and 48-week follow-up. The primary endpoint for this report was response to treatment based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI) remission and Disease Activity Score with 28 joints using C-reactive protein (DAS28-CRP) <2.6 stratified by BMI. Results Out of 793 people included in the present report, 161 (20%) had obesity at baseline. During follow-up, participants with baseline obesity had higher disease activity compared with those with lower BMI, despite having similar disease activity at baseline. In survival analyses, obesity was associated with a lower likelihood of achieving response to treatment during follow-up for up to 48 weeks (CDAI remission, HR 0.84, 95% CI 0.67 to 1.05; SDAI, HR 0.77, 95% CI 0.62 to 0.97; DAS28-CRP <2.6, HR 0.78, 95% CI 0.64 to 0.95). The effect of obesity on response to treatment was not influenced by the treatment arms. Conclusion In people with untreated early RA followed up for up to 48 weeks, obesity was associated with a lower likelihood of good treatment response, irrespective of the type of randomised treatment received., Objective This report from the NORD-STAR (Nordic Rheumatic Diseases Strategy Trials and Registries) trial aimed to determine if obesity is associated with response to conventional and biological antirheumatic treatment in early rheumatoid arthritis (RA). Methods This report included 793 participants with untreated early RA from the randomised, longitudinal NORD-STAR trial, all of whom had their body mass index (BMI) assessed at baseline. Obesity was defined as BMI ≥30 kg/m2. All participants were randomised 1:1:1:1 to one of four treatment arms: active conventional treatment, certolizumab-pegol, abatacept and tocilizumab. Clinical and laboratory measurements were performed at baseline and at 8, 12, 24 and 48-week follow-up. The primary endpoint for this report was response to treatment based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI) remission and Disease Activity Score with 28 joints using C-reactive protein (DAS28-CRP) <2.6 stratified by BMI. Results Out of 793 people included in the present report, 161 (20%) had obesity at baseline. During follow-up, participants with baseline obesity had higher disease activity compared with those with lower BMI, despite having similar disease activity at baseline. In survival analyses, obesity was associated with a lower likelihood of achieving response to treatment during follow-up for up to 48 weeks (CDAI remission, HR 0.84, 95% CI 0.67 to 1.05; SDAI, HR 0.77, 95% CI 0.62 to 0.97; DAS28-CRP <2.6, HR 0.78, 95% CI 0.64 to 0.95). The effect of obesity on response to treatment was not influenced by the treatment arms. Conclusion In people with untreated early RA followed up for up to 48 weeks, obesity was associated with a lower likelihood of good treatment response, irrespective of the type of randomised treatment received.
- Published
- 2024
28. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
- Author
-
Ørnbjerg, Lykke M., Rugbjerg, Kathrine, Georgiadis, Stylianos, Rasmussen, Simon H., Jacobsson, Lennart, Loft, Anne G., Iannone, Florenzo, Fagerli, Karen M., Vencovsky, Jiri, Santos, Maria J., Möller, Burkhard, Pombo-Suarez, Manuel, Rotar, Ziga, Gudbjornsson, Bjorn, Cefle, Ayse, Eklund, Kari, Codreanu, Catalin, Jones, Gareth, van der Sande, Marleen, Wallman, Johan K., Sebastiani, Marco, Michelsen, Brigitte, Závada, Jakub, Nissen, Michael J., Sanchez-Piedra, Carlos, Tomšič, Matija, Love, Thorvardur J., Relas, Heikki, Mogosan, Corina, Hetland, Merete L., Østergaard, Mikkel, Ørnbjerg, Lykke M., Rugbjerg, Kathrine, Georgiadis, Stylianos, Rasmussen, Simon H., Jacobsson, Lennart, Loft, Anne G., Iannone, Florenzo, Fagerli, Karen M., Vencovsky, Jiri, Santos, Maria J., Möller, Burkhard, Pombo-Suarez, Manuel, Rotar, Ziga, Gudbjornsson, Bjorn, Cefle, Ayse, Eklund, Kari, Codreanu, Catalin, Jones, Gareth, van der Sande, Marleen, Wallman, Johan K., Sebastiani, Marco, Michelsen, Brigitte, Závada, Jakub, Nissen, Michael J., Sanchez-Piedra, Carlos, Tomšič, Matija, Love, Thorvardur J., Relas, Heikki, Mogosan, Corina, Hetland, Merete L., and Østergaard, Mikkel
- Abstract
Objective To evaluate patient-reported outcomes (PROs) after initiation of tumor necrosis factor inhibitor (TNFi) treatment in European real-world patients with psoriatic arthritis (PsA). Further, to investigate PRO remission rates across treatment courses, registries, disease duration, sex, and age at disease onset. Methods Visual analog scale or numerical rating scale scores for pain, fatigue, patient global assessment (PtGA), and the Health Assessment Questionnaire–Disability Index (HAQ-DI) from 12,262 patients with PsA initiating a TNFi in 13 registries were pooled. PRO remission rates (pain ≤ 1, fatigue ≤ 2, PtGA ≤ 2, and HAQ-DI ≤ 0.5) were calculated for patients still on the treatment. Results For the first TNFi, median pain score was reduced by approximately 50%, from 6 to 3, 3, and 2; as were fatigue scores, from 6 to 4, 4, and 3; PtGA scores, from 6 to 3, 3, and 2; and HAQ-DI scores, from 0.9 to 0.5, 0.5, and 0.4 at baseline, 6, 12, and 24 months, respectively. Six-month Lund Efficacy Index (LUNDEX)–adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 24%, 31%, 36%, and 43% (first TNFi); 14%, 19%, 23%, and 29% (second TNFi); and 9%, 14%, 17%, and 20% (third TNFi), respectively. For biologic-naïve patients with disease duration < 5 years, 6-month LUNDEX-adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 22%, 28%, 33%, and 42%, respectively. Corresponding rates for patients with disease duration > 10 years were 27%, 32%, 41%, and 43%, respectively. Remission rates were 33%, 40%, 45%, and 56% for men and 17%, 23%, 24%, and 32% for women, respectively. For patients aged < 45 years at diagnosis, 6-month LUNDEX-adjusted remission rate for pain was 29% vs 18% for patients ≥ 45 years. Conclusion In 12,262 biologic-naïve patients with PsA, 6 months of treatment with a TNFi reduced pain by approximately 50%. Marked differences in PRO remission rates across treatment courses, registries, di, Objective. To evaluate patient-reported outcomes (PROs) after initiation of tumor necrosis factor inhibitor (TNFi) treatment in European real-world patients with psoriatic arthritis (PsA). Further, to investigate PRO remission rates across treatment courses, registries, disease duration, sex, and age at disease onset. Methods. Visual analog scale or numerical rating scale scores for pain, fatigue, patient global assessment (PtGA), and the Health Assessment Questionnaire–Disability Index (HAQ-DI) from 12,262 patients with PsA initiating a TNFi in 13 registries were pooled. PRO remission rates (pain ≤ 1, fatigue ≤ 2, PtGA ≤ 2, and HAQ-DI ≤ 0.5) were calculated for patients still on the treatment. Results. For the first TNFi, median pain score was reduced by approximately 50%, from 6 to 3, 3, and 2; as were fatigue scores, from 6 to 4, 4, and 3; PtGA scores, from 6 to 3, 3, and 2; and HAQ-DI scores, from 0.9 to 0.5, 0.5, and 0.4 at baseline, 6, 12, and 24 months, respectively. Six-month Lund Efficacy Index (LUNDEX)–adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 24%, 31%, 36%, and 43% (first TNFi); 14%, 19%, 23%, and 29% (second TNFi); and 9%, 14%, 17%, and 20% (third TNFi), respectively. For biologic-naïve patients with disease duration < 5 years, 6-month LUNDEX-adjusted remission rates for pain, fatigue, PtGA, and HAQ-DI scores were 22%, 28%, 33%, and 42%, respectively. Corresponding rates for patients with disease duration > 10 years were 27%, 32%, 41%, and 43%, respectively. Remission rates were 33%, 40%, 45%, and 56% for men and 17%, 23%, 24%, and 32% for women, respectively. For patients aged < 45 years at diagnosis, 6-month LUNDEX-adjusted remission rate for pain was 29% vs 18% for patients ≥ 45 years. Conclusion. In 12,262 biologic-naïve patients with PsA, 6 months of treatment with a TNFi reduced pain by approximately 50%. Marked differences in PRO remission rates across treatment courses, registries, disease duration, sex
- Published
- 2024
29. Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis:Results From the European Spondyloarthritis Research Collaboration Network
- Author
-
Hellamand, Pasoon, van de Sande, Marleen G.H., Ørnbjerg, Lykke M., Klausch, Thomas, Eklund, Kari K., Relas, Heikki, Santos, Maria J., Vieira-Sousa, Elsa, Loft, Anne G., Glintborg, Bente, Østergaard, Mikkel, Lindström, Ulf, Wallman, Johan K., Michelsen, Brigitte, Fagerli, Karen M., Castrejón, Isabel, Gudbjornsson, Bjorn, Love, Thorvardur J., Vencovský, Jiří, Nekvindová, Lucie, Rotar, Žiga, Tomšič, Matija, Díaz-González, Federico, Kenar, Gökçe, Tuğsal, Handan Y., Iannone, Florenzo, Ramonda, Roberta, Codreanu, Catalin, Mogosan, Corina, Nissen, Michael J., Möller, Burkhard, Hetland, Merete L., van der Horst-Bruinsma, Irene E., Hellamand, Pasoon, van de Sande, Marleen G.H., Ørnbjerg, Lykke M., Klausch, Thomas, Eklund, Kari K., Relas, Heikki, Santos, Maria J., Vieira-Sousa, Elsa, Loft, Anne G., Glintborg, Bente, Østergaard, Mikkel, Lindström, Ulf, Wallman, Johan K., Michelsen, Brigitte, Fagerli, Karen M., Castrejón, Isabel, Gudbjornsson, Bjorn, Love, Thorvardur J., Vencovský, Jiří, Nekvindová, Lucie, Rotar, Žiga, Tomšič, Matija, Díaz-González, Federico, Kenar, Gökçe, Tuğsal, Handan Y., Iannone, Florenzo, Ramonda, Roberta, Codreanu, Catalin, Mogosan, Corina, Nissen, Michael J., Möller, Burkhard, Hetland, Merete L., and van der Horst-Bruinsma, Irene E.
- Abstract
Objective Women with psoriatic arthritis (PsA) may have reduced tumor necrosis factor inhibitor (TNFi) effectiveness compared to men. We examined sex differences in treatment response and retention rates during 24 months of follow-up among patients with PsA initiating their first TNFi. Methods Data from patients with PsA across 13 European Spondyloarthritis Research Collaboration Network registries starting their first TNFi were pooled. Logistic regression was used to analyze the association between sex and treatment response using low disease activity (LDA) according to the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) (<3.2) at six months as the primary outcome. Analyses were adjusted for age, country, conventional synthetic disease-modifying antirheumatic drug treatment, and TNFi start year. Retention rates were explored using the Kaplan–Meier estimator. Results We analyzed the treatment response of 7,679 patients with PsA (50% women) with available data on LDA at six months. At baseline, women and men had similar characteristics, including mean DAS28-CRP (women vs men, 4.4 [SD 1.2] vs 4.2 [SD 1.2]), though patient-reported outcome measures were worse in women. At six months, 64% of women and 78% of men had LDA (relative risk [RR] 0.82; 95% confidence interval [CI] 0.80–0.84). This difference was similar after adjustment (RR 0.83; 95% CI 0.81–0.85). TNFi retention rates were evaluated in 17,842 patients with PsA. Women had significantly lower retention rates than men at all time points (women 79%, 64%, and 50% vs men 88%, 77%, and 64% at 6, 12, and 24 months, respectively). Conclusion Despite comparable disease characteristics at baseline, women with PsA have reduced treatment response and retention rates to their first TNFi, highlighting the need to consider sex differences in PsA research and management., Objective: Women with psoriatic arthritis (PsA) may have reduced tumor necrosis factor inhibitor (TNFi) effectiveness compared to men. We examined sex differences in treatment response and retention rates during 24 months of follow-up among patients with PsA initiating their first TNFi. Methods: Data from patients with PsA across 13 European Spondyloarthritis Research Collaboration Network registries starting their first TNFi were pooled. Logistic regression was used to analyze the association between sex and treatment response using low disease activity (LDA) according to the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) (<3.2) at six months as the primary outcome. Analyses were adjusted for age, country, conventional synthetic disease-modifying antirheumatic drug treatment, and TNFi start year. Retention rates were explored using the Kaplan–Meier estimator. Results: We analyzed the treatment response of 7,679 patients with PsA (50% women) with available data on LDA at six months. At baseline, women and men had similar characteristics, including mean DAS28-CRP (women vs men, 4.4 [SD 1.2] vs 4.2 [SD 1.2]), though patient-reported outcome measures were worse in women. At six months, 64% of women and 78% of men had LDA (relative risk [RR] 0.82; 95% confidence interval [CI] 0.80–0.84). This difference was similar after adjustment (RR 0.83; 95% CI 0.81–0.85). TNFi retention rates were evaluated in 17,842 patients with PsA. Women had significantly lower retention rates than men at all time points (women 79%, 64%, and 50% vs men 88%, 77%, and 64% at 6, 12, and 24 months, respectively). Conclusion: Despite comparable disease characteristics at baseline, women with PsA have reduced treatment response and retention rates to their first TNFi, highlighting the need to consider sex differences in PsA research and management.
- Published
- 2024
30. Long-Term efficacy of a 2-year MRI treat-To-Target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission:5-year follow-up of the IMAGINE-RA randomised trial
- Author
-
Møller-Bisgaard, Signe, Hørslev-Petersen, Kim, Ørnbjerg, Lykke Midtbøll, Ejbjerg, Bo, Hetland, Merete Lund, Møller, Jakob Møllenbach, Nielsen, Sabrina Mai, Glinatsi, Daniel, Boesen, Mikael, Stengaard-Pedersen, Kristian, Madsen, Ole Rintek, Jensen, Bente, Villadsen, Jan Alexander, Hauge, Ellen Margrethe, Hendricks, Oliver, Lindegaard, Hanne, Krogh, Niels Steen, Jurik, Anne Grethe, Thomsen, Henrik, Christensen, Robin, Østergaard, Mikkel, Møller-Bisgaard, Signe, Hørslev-Petersen, Kim, Ørnbjerg, Lykke Midtbøll, Ejbjerg, Bo, Hetland, Merete Lund, Møller, Jakob Møllenbach, Nielsen, Sabrina Mai, Glinatsi, Daniel, Boesen, Mikael, Stengaard-Pedersen, Kristian, Madsen, Ole Rintek, Jensen, Bente, Villadsen, Jan Alexander, Hauge, Ellen Margrethe, Hendricks, Oliver, Lindegaard, Hanne, Krogh, Niels Steen, Jurik, Anne Grethe, Thomsen, Henrik, Christensen, Robin, and Østergaard, Mikkel
- Abstract
Objective To investigate whether a 2-year MRI treat-to-target strategy targeting the absence of osteitis combined with clinical remission, compared with a conventional treat-to-target strategy targeting clinical remission only (IMAGINE-rheumatoid arthritis (RA) trial) improves clinical and radiographic outcomes over 5 years in patients with RA in clinical remission. Methods IMAGINE-more was an observational extension study of the original 2-year IMAGINE-RA randomised trial (NCT01656278). Clinical examinations and radiographs (hands and feet) were obtained yearly. Prespecified coprimary outcomes at year 5 were Disease Activity Score in 28 joints C reactive protein (DAS28-CRP) remission rate (DAS28-CRP<2.6) and no radiographic progression (van der Heijde-modified Sharp score (vdHSS) ≤0) from baseline. Secondary outcomes included 5-year changes in radiographic, MRI and clinical measures of disease activity and physical function. Results In total 131 patients, 86 women (67%), mean age 61.2, disease duration 9.5 years, median baseline DAS28-CRP 1.9 (IQR 1.6–2.2) and vdHSS 16.0 (IQR 7.0–36.0) were included in the study; 59 (59%) patients from the original MRI treat-to-target group and 72 (72%) from the conventional group. At year 5, 47 patients (80%) in the MRI treat-to-target group vs 54 patients (75%) in the conventional treat-to-target group were in DAS28-CRP remission (OR 2.00 (95% CI 0.76 to 5.28); p=0.16) while 14 patients (24%) vs 19 patients (26%) had no radiographic progression (OR 0.70, (95% CI 0.28 to 1.71); p=0.43). Conclusion A 2-year combined MRI and clinical treat-to-target strategy, compared with a conventional clinical treat-to-target strategy alone, had no effect on the long-term probability of achieving DAS28-CRP remission and of avoiding radiographic progression., Objective To investigate whether a 2-year MRI treat-To-Target strategy targeting the absence of osteitis combined with clinical remission, compared with a conventional treat-To-Target strategy targeting clinical remission only (IMAGINE-rheumatoid arthritis (RA) trial) improves clinical and radiographic outcomes over 5 years in patients with RA in clinical remission. Methods IMAGINE-more was an observational extension study of the original 2-year IMAGINE-RA randomised trial (NCT01656278). Clinical examinations and radiographs (hands and feet) were obtained yearly. Prespecified coprimary outcomes at year 5 were Disease Activity Score in 28 joints C reactive protein (DAS28-CRP) remission rate (DAS28-CRP<2.6) and no radiographic progression (van der Heijde-modified Sharp score (vdHSS) ≤0) from baseline. Secondary outcomes included 5-year changes in radiographic, MRI and clinical measures of disease activity and physical function. Results In total 131 patients, 86 women (67%), mean age 61.2, disease duration 9.5 years, median baseline DAS28-CRP 1.9 (IQR 1.6-2.2) and vdHSS 16.0 (IQR 7.0-36.0) were included in the study; 59 (59%) patients from the original MRI treat-To-Target group and 72 (72%) from the conventional group. At year 5, 47 patients (80%) in the MRI treat-To-Target group vs 54 patients (75%) in the conventional treat-To-Target group were in DAS28-CRP remission (OR 2.00 (95% CI 0.76 to 5.28); p=0.16) while 14 patients (24%) vs 19 patients (26%) had no radiographic progression (OR 0.70, (95% CI 0.28 to 1.71); p=0.43). Conclusion A 2-year combined MRI and clinical treat-To-Target strategy, compared with a conventional clinical treat-To-Target strategy alone, had no effect on the long-Term probability of achieving DAS28-CRP remission and of avoiding radiographic progression.
- Published
- 2024
31. Complement Proteins L-Ficolin and M-Ficolin Are Increased in Patients With Axial Spondyloarthritis and Decrease After Tumor Necrosis Factor Inhibitor Treatment
- Author
-
Mistegaard, Clara Elbæk, Troldborg, Anne, Hansen, Annette, Thiel, Steffen, Jurik, Anne Grethe, Kiil, Rosa M., Christiansen, Alice A., Schiøttz-Christensen, Berit, Hendricks, Oliver, Pedersen, Susanne Juhl, Sørensen, Inge Juul, Østergaard, Mikkel, Loft, Anne Gitte, Mistegaard, Clara Elbæk, Troldborg, Anne, Hansen, Annette, Thiel, Steffen, Jurik, Anne Grethe, Kiil, Rosa M., Christiansen, Alice A., Schiøttz-Christensen, Berit, Hendricks, Oliver, Pedersen, Susanne Juhl, Sørensen, Inge Juul, Østergaard, Mikkel, and Loft, Anne Gitte
- Abstract
Objective. We have previously reported elevated levels of the complement lectin pathway proteins L-ficolin and H-ficolin in patients with axial spondyloarthritis (axSpA) compared with healthy controls. The aim of the present study was to investigate these biomarkers in a cross-sectional cohort of patients suffering from low back pain (LBP). Further, we aimed to investigate changes in lectin pathway protein levels after initiation of adalimumab (ADA; a tumor necrosis factor inhibitor) in a longitudinal cohort of patients with axSpA. Methods. Lectin pathway protein levels (mannan-binding lectin [MBL], collectin liver 1, H-ficolin, L-ficolin, M-ficolin, MBL-associated serine protease [MASP]-1, MASP-2, MASP-3, MBL-associated protein 19 [MAp19], and MAp44) in EDTA plasma were determined in 2 well-characterized cohorts: (1) a clinical cross-sectional cohort of patients with LBP, including patients with axSpA (n = 23), patients with unspecific LBP (uLBP) with ≥ 1 SpA features (n = 55), and patients with uLBP without SpA features or magnetic resonance imaging findings suggestive of axSpA (n = 64); and (2) a randomized double-blinded, placebo-controlled trial cohort of patients with axSpA (n = 49) initiating ADA therapy. Lectin pathway protein levels were determined using immunoassays. Results. Plasma levels of L-ficolin and M-ficolin were significantly increased in the cross-sectional cohort of newly diagnosed patients with axSpA compared with clinically relevant controls with uLBP (all P < 0.05). Both L-ficolin and M-ficolin decreased significantly after ADA therapy (P < 0.05). Conclusion. L-ficolin and M-ficolin levels are elevated in newly diagnosed patients with axSpA compared with clinically relevant controls. Both L-ficolin and M-ficolin levels decrease significantly after initiating ADA therapy. These findings provide new insights into the inflammatory processes in axSpA and support the involvement of complement in axSpA pathogenesis.
- Published
- 2024
32. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor:results from 13 European registries
- Author
-
Linde, Louise, Ørnbjerg, Lykke M., Georgiadis, Stylianos, Rasmussen, Simon H., Lindström, Ulf, Askling, Johan, Michelsen, Brigitte, Di Giuseppe, Daniela, Wallman, Johan K., Gudbjornsson, Bjorn, Love, Thorvardur Jon, Nordström, Dan C., Yli-Kerttula, Timo, Nekvindová, Lucie, Vencovský, Jiří, Iannone, Florenzo, Cauli, Alberto, Loft, Anne Gitte, Glintborg, Bente, Laas, Karin, Rotar, Ziga, Tomšič, Matija, MacFarlane, Gary J., Möller, Burkhard, Van De Sande, Marleen, Codreanu, Catalin, Nissen, Michael J., Birlik, Merih, Erten, Sukran, Santos, Maria J., Vieira-Sousa, Elsa, Hetland, Merete L., Østergaard, Mikkel, Linde, Louise, Ørnbjerg, Lykke M., Georgiadis, Stylianos, Rasmussen, Simon H., Lindström, Ulf, Askling, Johan, Michelsen, Brigitte, Di Giuseppe, Daniela, Wallman, Johan K., Gudbjornsson, Bjorn, Love, Thorvardur Jon, Nordström, Dan C., Yli-Kerttula, Timo, Nekvindová, Lucie, Vencovský, Jiří, Iannone, Florenzo, Cauli, Alberto, Loft, Anne Gitte, Glintborg, Bente, Laas, Karin, Rotar, Ziga, Tomšič, Matija, MacFarlane, Gary J., Möller, Burkhard, Van De Sande, Marleen, Codreanu, Catalin, Nissen, Michael J., Birlik, Merih, Erten, Sukran, Santos, Maria J., Vieira-Sousa, Elsa, Hetland, Merete L., and Østergaard, Mikkel
- Abstract
Objectives In bio-naïve patients with PsA initiating a TNF inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries. Methods Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes were defined as common predictors. Results In the pooled cohort (n = 13 369), 6-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n = 6954, n = 5275 and n = 13 369, respectively). Five common baseline predictors of remission, moderate response and 12-month drug retention were identified across all three outcomes. The odds ratios (95% CIs) for DAPSA28 remission were: age, per year: 0.97 (0.96–0.98); disease duration, years (<2 years as reference): 2–3 years: 1.20 (0.89–1.60), 4–9 years: 1.42 (1.09–1.84), ≥10 years: 1.66 (1.26–2.20); men vs women: 1.85 (1.54–2.23); CRP of >10 vs ≤10 mg/l: 1.52 (1.22–1.89) and 1 mm increase in patient fatigue score: 0.99 (0.98–0.99). Conclusion Baseline predictors of remission, response and adherence to TNFi therapy were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalizable from country level to disease level., Objectives: In bio-naïve patients with PsA initiating a TNF inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries. Methods: Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes were defined as common predictors. Results: In the pooled cohort (n=13 369), 6-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n=6954, n=5275 and n=13 369, respectively). Five common baseline predictors of remission, moderate response and 12-month drug retention were identified across all three outcomes. The odds ratios (95% CIs) for DAPSA28 remission were: age, per year: 0.97 (0.96-0.98); disease duration, years (<2 years as reference): 2-3 years: 1.20 (0.89-1.60), 4-9 years: 1.42 (1.09-1.84), ≥10 years: 1.66 (1.26-2.20); men vs women: 1.85 (1.54-2.23); CRP of >10 vs ≤10 mg/l: 1.52 (1.22-1.89) and 1mm increase in patient fatigue score: 0.99 (0.98-0.99). Conclusion: Baseline predictors of remission, response and adherence to TNFi therapy were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalizable from country level to disease level.
- Published
- 2024
33. Low incidence of malignancy in patients with suspected polymyalgia rheumatica or giant cell arteritis, examined with FDG-PET/CT
- Author
-
Gorlen, Tanja Fromberg, Brittain, Jane Maestri, Østergaard, Mikkel, Fischer, Barbara Malene, Døhn, Uffe Møller, Terslev, Lene, Gorlen, Tanja Fromberg, Brittain, Jane Maestri, Østergaard, Mikkel, Fischer, Barbara Malene, Døhn, Uffe Møller, and Terslev, Lene
- Abstract
Introduction: The need to systematically examine patients suspected of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) for malignancy is controversial. The aim of this study was to assess the frequency of malignancy in patients with suspected PMR and/or GCA who have been referred to a 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography (FDG-PET/CT) as part of the diagnostic investigation. Method: The records of all patients referred to FDG-PET/CT from Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup with the suspicion of PMR and/or GCA during a two-year period, were retrospectively reviewed. Data was analyzed with descriptive statistics, and a standard incidence ratio was calculated based on background cancer incidences extracted from the NORDCAN database. Results: 220 patients were included in the study. Findings suspicious of malignancy were found in 19 of the examinations, and in seven cases (3.2%), malignancy was confirmed. In three out of the seven cases the patients were diagnosed with PMR concomitantly with malignancy. The estimated standardized incidence ratio (SIR) for cancer compared to the background incidence of cancer in Denmark was 1.58 (95% CI 0.63–2.97), i.e., not statistically significant. There were no statistically significant differences in characteristics of the patients that were diagnosed with malignancy compared with those that were not. Conclusion: The frequency of malignancy in this cohort of patients with suspected PMR/GCA who underwent PET/CT was low. Our results, though based on a small cohort, do not suggest that all patients with suspected PMR/GCA should systematically be examined with FDG-PET/CT for excluding malignancy.
- Published
- 2024
34. Solid validity evidence for two tools assessing competences in musculoskeletal ultrasound:a validity study
- Author
-
Carstensen, Stine Maya Dreier, Just, Søren Andreas, Pfeiffer-Jensen, Mogens, Østergaard, Mikkel, Konge, Lars, Terslev, Lene, Carstensen, Stine Maya Dreier, Just, Søren Andreas, Pfeiffer-Jensen, Mogens, Østergaard, Mikkel, Konge, Lars, and Terslev, Lene
- Abstract
Objectives Musculoskeletal ultrasound (MSUS) is increasingly used by rheumatologists in daily clinical practice. However, MSUS is only valuable in trained hands, and assessment of trainee competences is therefore essential before independent practice. Thus, this study aimed to establish validity evidence for the EULAR and the Objective Structured Assessment of Ultrasound Skills (OSAUS) tools used for assessing MSUS competences. Methods Thirty physicians with different levels of MSUS experience (novices, intermediates, and experienced) performed four MSUS examinations of different joint areas on the same rheumatoid arthritis patient. All examinations were video recorded (n = 120), anonymized, and subsequently assessed in random order by two blinded raters using first the OSAUS assessment tool followed by the EULAR tool 1 month after. Results The inter-rater reliability between the two raters was high for both the OSAUS and EULAR tools, with a Pearson correlation coefficient (PCC) of 0.807 and 0.848, respectively. Both tools demonstrated excellent inter-case reliability, with a Cronbach’s alpha of 0.970 for OSAUS and 0.964 for EULAR. Furthermore, there was a strong linear correlation between the OSAUS and the EULAR performance scores and the participants’ experience levels (R2 = 0.897 and R2 = 0.868, respectively) and a significant discrimination between different MSUS experience levels (P < 0.001 for both). Conclusions MSUS operator competences can be assessed reliably and valid using either the OSAUS or the EULAR assessment tool, thereby allowing a uniform competency-based MSUS education in the future. Although both tools demonstrated high inter-rater reliability, the EULAR tool was superior to OSAUS. Trial registration ClinicalTrials.gov, http://clinicaltrials.gov, NCT05256355, Objectives: Musculoskeletal ultrasound (MSUS) is increasingly used by rheumatologists in daily clinical practice. However, MSUS is only valuable in trained hands, and assessment of trainee competences is therefore essential before independent practice. Thus, this study aimed to establish validity evidence for the EULAR and the Objective Structured Assessment of Ultrasound Skills (OSAUS) tools used for assessing MSUS competences. Methods: Thirty physicians with different levels of MSUS experience (novices, intermediates, and experienced) performed four MSUS examinations of different joint areas on the same rheumatoid arthritis patient. All examinations were video recorded (n=120), anonymized, and subsequently assessed in random order by two blinded raters using first the OSAUS assessment tool followed by the EULAR tool 1 month after. Results: The inter-rater reliability between the two raters was high for both the OSAUS and EULAR tools, with a Pearson correlation coefficient (PCC) of 0.807 and 0.848, respectively. Both tools demonstrated excellent inter-case reliability, with a Cronbach's alpha of 0.970 for OSAUS and 0.964 for EULAR. Furthermore, there was a strong linear correlation between the OSAUS and the EULAR performance scores and the participants' experience levels (R2=0.897 and R2=0.868, respectively) and a significant discrimination between different MSUS experience levels (P<0.001 for both). Conclusions: MSUS operator competences can be assessed reliably and valid using either the OSAUS or the EULAR assessment tool, thereby allowing a uniform competency-based MSUS education in the future. Although both tools demonstrated high inter-rater reliability, the EULAR tool was superior to OSAUS.
- Published
- 2024
35. Validation of SPARCC MRI-RETIC e-tools for increasing scoring proficiency of MRI sacroiliac joint lesions in axial spondyloarth
- Author
-
Maksymowych, Walter, Hadsbjerg, Anna Enevold Fløistrup E.F., Østergaard, Mikkel, Micheroli, Raphael, Pedersen, Susanne Juhl, Ciurea, Adrian, Vladimirova, Nora, Nissen, Michael S., Bubova, Kristyna, Wichuk, Stephanie, de Hooge, Manouk, Mathew, Ashish J., Pintaric, Karlo, Gregová, Monika, Snoj, Ziga, Wetterslev, Marie, Gorican, Karel, Möller, Burkhard, Eshed, Iris, Paschke, Joel, Lambert, Robert Gw, Maksymowych, Walter, Hadsbjerg, Anna Enevold Fløistrup E.F., Østergaard, Mikkel, Micheroli, Raphael, Pedersen, Susanne Juhl, Ciurea, Adrian, Vladimirova, Nora, Nissen, Michael S., Bubova, Kristyna, Wichuk, Stephanie, de Hooge, Manouk, Mathew, Ashish J., Pintaric, Karlo, Gregová, Monika, Snoj, Ziga, Wetterslev, Marie, Gorican, Karel, Möller, Burkhard, Eshed, Iris, Paschke, Joel, and Lambert, Robert Gw
- Abstract
Background The Spondyloarthritis Research Consortium of Canada (SPARCC) developers have created web-based calibration modules for the SPARCC MRI sacroiliac joint (SIJ) scoring methods. We aimed to test the impact of applying these e-modules on the feasibility and reliability of these methods. Methods The SPARCC-SIJRETIC e-modules contain cases with baseline and follow-up scans and an online scoring interface. Visual real-time feedback regarding concordance/discordance of scoring with expert readers is provided by a colour-coding scheme. Reliability is assessed in real time by intraclass correlation coefficient (ICC), cases being scored until ICC targets are attained. Participating readers (n=17) from the EuroSpA Imaging project were randomised to one of two reader calibration strategies that each comprised three stages. Baseline and follow-up scans from 25 cases were scored after each stage was completed. Reliability was compared with a SPARCC developer, and the System Usability Scale (SUS) assessed feasibility. Results The reliability of readers for scoring bone marrow oedema was high after the first stage of calibration, and only minor improvement was noted following the use of the inflammation module. Greater enhancement of reader reliability was evident after the use of the structural module and was most consistently evident for the scoring of erosion (ICC status/change: stage 1 (0.42/0.20) to stage 3 (0.50/0.38)) and backfill (ICC status/change: stage 1 (0.51/0.19) to stage 3 (0.69/0.41)). The feasibility of both e-modules was evident by high SUS scores. Conclusion The SPARCC-SIJRETIC e-modules are feasible, effective knowledge transfer tools, and their use is recommended before using the SPARCC methods for clinical research and tria, BACKGROUND: The Spondyloarthritis Research Consortium of Canada (SPARCC) developers have created web-based calibration modules for the SPARCC MRI sacroiliac joint (SIJ) scoring methods. We aimed to test the impact of applying these e-modules on the feasibility and reliability of these methods. METHODS: The SPARCC-SIJ RETIC e-modules contain cases with baseline and follow-up scans and an online scoring interface. Visual real-time feedback regarding concordance/discordance of scoring with expert readers is provided by a colour-coding scheme. Reliability is assessed in real time by intraclass correlation coefficient (ICC), cases being scored until ICC targets are attained. Participating readers (n=17) from the EuroSpA Imaging project were randomised to one of two reader calibration strategies that each comprised three stages. Baseline and follow-up scans from 25 cases were scored after each stage was completed. Reliability was compared with a SPARCC developer, and the System Usability Scale (SUS) assessed feasibility. RESULTS: The reliability of readers for scoring bone marrow oedema was high after the first stage of calibration, and only minor improvement was noted following the use of the inflammation module. Greater enhancement of reader reliability was evident after the use of the structural module and was most consistently evident for the scoring of erosion (ICC status/change: stage 1 (0.42/0.20) to stage 3 (0.50/0.38)) and backfill (ICC status/change: stage 1 (0.51/0.19) to stage 3 (0.69/0.41)). The feasibility of both e-modules was evident by high SUS scores. CONCLUSION: The SPARCC-SIJ RETIC e-modules are feasible, effective knowledge transfer tools, and their use is recommended before using the SPARCC methods for clinical research and tria.
- Published
- 2024
36. Ultrasound in the Management of Patients With Psoriatic Arthritis:Systematic Literature Review and Novel Algorithms for Pragmatic Use
- Author
-
Gouze, Hélène, Backhaus, Marina, Balint, Peter, Matteo, Andrea Di, Grassi, Walter, Iagnocco, Annamaria, Naredo, Esperanza, Wakefield, Richard J., Østergaard, Mikkel, Emery, Paul, D’Agostino, Maria Antonietta, Gouze, Hélène, Backhaus, Marina, Balint, Peter, Matteo, Andrea Di, Grassi, Walter, Iagnocco, Annamaria, Naredo, Esperanza, Wakefield, Richard J., Østergaard, Mikkel, Emery, Paul, and D’Agostino, Maria Antonietta
- Abstract
Objective In 2015, the European Alliance of Associations for Rheumatology (EULAR) published recommendations for the use of imaging for the diagnosis and management of spondyloarthritis (SpA) in clinical practice. These recommendations included the use of ultrasound (US) in patients with psoriatic arthritis (PsA), but the management was not clearly distinguished from that of SpA. We aimed to systematically review the literature on the role of US for the management of PsA, and to propose pragmatic algorithms for its use in clinical practice. Methods A group of 10 rheumatologists, experienced in imaging and musculoskeletal US, met with the objectives of formulating key questions for a systematic literature review (SLR), appraising the available evidence, and then proposing algorithms on the application of US in suspected or established PsA, based on both the literature and experts’ opinions following a Delphi process. Results The SLR included 120 articles, most of which focused on the diagnostic process. The elevated number of articles retrieved suggests the interest of rheumatologists in using US in the management of PsA. After a consensual discussion on literature data and expert opinion, the following 3 algorithms were developed to be used in practical situations: suspicion of PsA, management of PsA with good clinical response, and management of PsA with insufficient clinical response. Conclusion The SLR showed interest by rheumatologists in using US to objectively evaluate PsA for diagnosis and management. We propose 3 practical algorithms to guide its use in the clinical management of patients, from diagnosis to the assessment of treatment response. Further studies are needed to define remission and to assess the ability of US to predict disease severity., Objective. In 2015, the European Alliance of Associations for Rheumatology (EULAR) published recommendations for the use of imaging for the diagnosis and management of spondyloarthritis (SpA) in clinical practice. These recommendations included the use of ultrasound (US) in patients with psoriatic arthritis (PsA), but the management was not clearly distinguished from that of SpA. We aimed to systematically review the literature on the role of US for the management of PsA, and to propose pragmatic algorithms for its use in clinical practice. Methods. A group of 10 rheumatologists, experienced in imaging and musculoskeletal US, met with the objectives of formulating key questions for a systematic literature review (SLR), appraising the available evidence, and then proposing algorithms on the application of US in suspected or established PsA, based on both the literature and experts’ opinions following a Delphi process. Results. The SLR included 120 articles, most of which focused on the diagnostic process. The elevated number of articles retrieved suggests the interest of rheumatologists in using US in the management of PsA. After a consensual discussion on literature data and expert opinion, the following 3 algorithms were developed to be used in practical situations: suspicion of PsA, management of PsA with good clinical response, and management of PsA with insufficient clinical response. Conclusion. The SLR showed interest by rheumatologists in using US to objectively evaluate PsA for diagnosis and management. We propose 3 practical algorithms to guide its use in the clinical management of patients, from diagnosis to the assessment of treatment response. Further studies are needed to define remission and to assess the ability of US to predict disease severity.
- Published
- 2024
37. Occurrence and Prediction of Flare After Tapering of Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis
- Author
-
Wetterslev, Marie, Georgiadis, Stylianos, Christiansen, Sara Nysom, Pedersen, Susanne Juhl, Sørensen, Inge Juul, Hetland, Merete Lund, Duer, Anne, Boesen, Mikael, Gosvig, Kasper Kjærulf, Møller, Jakob Møllenbach, Bakkegaard, Mads, Brahe, Cecilie Heegaard, Krogh, Niels Steen, Jensen, Bente, Madsen, Ole Rintek, Christensen, Jan, Hansen, Annette, Nørregaard, Jesper, Røgind, Henrik, Østergaard, Mikkel, Wetterslev, Marie, Georgiadis, Stylianos, Christiansen, Sara Nysom, Pedersen, Susanne Juhl, Sørensen, Inge Juul, Hetland, Merete Lund, Duer, Anne, Boesen, Mikael, Gosvig, Kasper Kjærulf, Møller, Jakob Møllenbach, Bakkegaard, Mads, Brahe, Cecilie Heegaard, Krogh, Niels Steen, Jensen, Bente, Madsen, Ole Rintek, Christensen, Jan, Hansen, Annette, Nørregaard, Jesper, Røgind, Henrik, and Østergaard, Mikkel
- Abstract
Objective Patients with axial spondyloarthritis (axSpA) in clinical remission tapered tumor necrosis factor inhibitor (TNFi) therapy according to a clinical guideline. Over a 2-year follow-up period, we aimed to investigate flare frequency, dose at which flare occurred, type of flare, and predictors thereof. Methods Patients in clinical remission (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] < 40, physician global score < 40, and without disease activity the previous year) tapered TNFi to two-thirds the standard dose at baseline, half at week 16, one-third at week 32, and discontinued at week 48. Flares were defined as BASDAI flare (BASDAI ≥ 40 and change ≥ 20 since inclusion), and/or clinical flare (development of inflammatory back pain, musculoskeletal or extraarticular manifestations, and/or Ankylosing Spondylitis Disease Activity Score [ASDAS] ≥ 0.9), and/or magnetic resonance imaging (MRI) flare (≥ 2 new or worsened inflammatory lesions). Results Of 108 patients, 106 (99%) flared before 2-year follow-up: 29 patients (27%) at two-thirds standard dose, 21 (20%) at half dose, 29 (27%) at one-third dose, and 27 (25%) after discontinuation. Regarding type of flare, 105 (99%) had clinical flares, 25 (24%) had BASDAI flares, and 23 (29% of patients with MRI at flare available) had MRI flares. Forty-one patients (41%) fulfilled the Assessment of SpondyloArthritis international Society (ASAS) definition of clinically important worsening (≥ 0.9 increase since baseline). Higher baseline physician global score was an independent predictor of flare after tapering to two-thirds (OR 1.19, 95% CI 1.04-1.41, P = 0.01). Changes in clinical and/or imaging variables in the 16 weeks prior to tapering did not predict flare. Conclusion Almost all (99%) patients with axSpA in clinical remission experienced flare during tapering to discontinuation, but in over half of these patients, flare did not occur before receiving one-third dose or, Objective. Patients with axial spondyloarthritis (axSpA) in clinical remission tapered tumor necrosis factor inhibitor (TNFi) therapy according to a clinical guideline. Over a 2-year follow-up period, we aimed to investigate flare frequency, dose at which flare occurred, type of flare, and predictors thereof. Methods. Patients in clinical remission (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] < 40, physician global score < 40, and without disease activity the previous year) tapered TNFi to two-thirds the standard dose at baseline, half at week 16, one-third at week 32, and discontinued at week 48. Flares were defined as BASDAI flare (BASDAI ≥ 40 and change ≥ 20 since inclusion), and/or clinical flare (development of inflammatory back pain, musculoskeletal or extraarticular manifestations, and/or Ankylosing Spondylitis Disease Activity Score [ASDAS] ≥ 0.9), and/or magnetic resonance imaging (MRI) flare (≥ 2 new or worsened inflammatory lesions). Results. Of 108 patients, 106 (99%) flared before 2-year follow-up: 29 patients (27%) at two-thirds standard dose, 21 (20%) at half dose, 29 (27%) at one-third dose, and 27 (25%) after discontinuation. Regarding type of flare, 105 (99%) had clinical flares, 25 (24%) had BASDAI flares, and 23 (29% of patients with MRI at flare available) had MRI flares. Forty-one patients (41%) fulfilled the Assessment of SpondyloArthritis international Society (ASAS) definition of clinically important worsening (≥ 0.9 increase since baseline). Higher baseline physician global score was an independent predictor of flare after tapering to two-thirds (OR 1.19, 95% CI 1.04-1.41, P = 0.01). Changes in clinical and/or imaging variables in the 16 weeks prior to tapering did not predict flare. Conclusion. Almost all (99%) patients with axSpA in clinical remission experienced flare during tapering to discontinuation, but in over half of these patients, flare did not occur before receiving one-third dose or less. Higher physici
- Published
- 2024
38. Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head‐to‐Head Randomized Phase IIIb Study.
- Author
-
Baraliakos, Xenofon, Østergaard, Mikkel, Poddubnyy, Denis, van der Heijde, Désirée, Deodhar, Atul, Machado, Pedro M., Navarro‐Compán, Victoria, Hermann, Kay Geert A., Kishimoto, Mitsumasa, Lee, Eun Young, Gensler, Lianne S., Kiltz, Uta, Eigenmann, Marco F., Pertel, Patricia, Readie, Aimee, Richards, Hanno B., Porter, Brian, and Braun, Juergen
- Subjects
- *
COMBINATION drug therapy , *ANTI-inflammatory agents , *RESEARCH funding , *PATIENT safety , *ANKYLOSIS , *EDEMA , *LOGISTIC regression analysis , *QUESTIONNAIRES , *DESCRIPTIVE statistics , *MAGNETIC resonance imaging , *ANALYSIS of covariance , *CHI-squared test , *MONOCLONAL antibodies , *ADALIMUMAB , *DRUG efficacy , *INTRACLASS correlation , *BIOSIMILARS , *SPONDYLOARTHROPATHIES , *HEALTH outcome assessment , *CONFIDENCE intervals , *DATA analysis software , *DISEASE progression , *INTERLEUKINS , *C-reactive protein , *DRUG tolerance , *SUBCUTANEOUS injections , *DRUG dosage , *DRUG administration , *CHEMICAL inhibitors - Abstract
Objective: Spinal radiographic progression is an important outcome in radiographic axial spondyloarthritis (SpA). The objective of the phase IIIb SURPASS study was to compare spinal radiographic progression in patients with radiographic axial SpA treated with secukinumab (interleukin‐17A inhibitor) versus adalimumab biosimilar (Sandoz adalimumab [SDZ‐ADL]; tumor necrosis factor inhibitor). Methods: Biologic‐naive patients with active radiographic axial SpA, at high risk of radiographic progression (high‐sensitivity C‐reactive protein [hsCRP] ≥5 mg/L and/or ≥1 syndesmophyte[s] on spinal radiographs), were randomized (1:1:1) to secukinumab (150/300 mg) or SDZ‐ADL (40 mg). The proportion of patients with no radiographic progression (change from baseline [CFB] in modified Stoke Ankylosing Spondylitis Spinal Score [mSASSS] ≤0.5) on secukinumab versus SDZ‐ADL at week 104 (primary endpoint), mean CFB‐mSASSS, proportion of patients with ≥1 syndesmophyte(s) at baseline with no new syndesmophyte(s), and safety were evaluated. Results: Overall, 859 patients (78.5% male, mSASSS 16.6, Bath Ankylosing Spondylitis Disease Activity Index 7.1, hsCRP 20.4 mg/L, and 73.0% with ≥1 syndesmophyte[s]) received secukinumab 150 mg (n = 287), secukinumab 300 mg (n = 286), or SDZ‐ADL (n = 286). At week 104, the proportion of patients with no radiographic progression was 66.1%, 66.9%, and 65.6% (P = not significant, both secukinumab doses) and mean CFB‐mSASSS was 0.54, 0.55, and 0.72 in secukinumab 150 mg, secukinumab 300 mg, and SDZ‐ADL arms, respectively. Overall, 56.9%, 53.8%, and 53.3% of patients on secukinumab 150 mg, secukinumab 300 mg, and SDZ‐ADL, respectively, with ≥1 syndesmophyte(s) at baseline did not develop new syndesmophyte(s) by week 104. There were no unexpected safety findings. Conclusion: Spinal radiographic progression over two years was low with no significant difference between secukinumab and SDZ‐ADL arms. The safety of both treatments was consistent with previous reports. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Evidence for routine brain‐to‐pelvis imaging and antiplatelet therapy in patients diagnosed with fibromuscular dysplasia.
- Author
-
Østergaard, Mikkel Landgraff, Hjort, Niels, Buus, Niels Henrik, and Reinhard, Mark
- Abstract
Fibromuscular dysplasia (FMD) is a disease of the musculature of arterial walls leading to stenoses, aneurysms, and dissections. The purpose of this report was to summarize the evidence for (1) one‐time routine imaging from brain‐to‐pelvis and (2) lifelong antiplatelet therapy, for example, aspirin, for patients diagnosed with FMD as suggested by an international consensus report from 2019. PubMed was systematically searched, and the evidence providing a basis for the current consensus points, as well as articles published since, were reviewed. In four registries evaluating patients with FMD, the prevalence of multivessel involvement, aneurysms, and dissections was reported to be 43.5%–66.3%, 21.6%–30.6%, and 5.6%–28.1%, respectively. Any antiplatelet drug was used in 72.9% of patients, and aspirin was prescribed in up to 70.2% of patients. Based on the high prevalence of vascular manifestations, their associated morbidity, and the potential for endovascular or surgical intervention, the suggestion of one‐time brain‐to‐pelvis screening with computed tomography angiography or magnetic resonance angiography is well supported. Contrarily, the evidence to support the consensus statement of lifelong antiplatelet therapy to all patients in the absence of contraindications is more uncertain since a beneficial effect has not been demonstrated specifically in patients with fibromuscular dysplasia. Therefore, until the efficacy and safety of primary thromboprophylaxis have been demonstrated in this patient group specifically, it may be equally appropriate to only use antiplatelet agents in patients with a clear indication after individual evaluation according to risk factors for thrombotic and thromboembolic complications. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Peripheral Joint and Enthesis Involvement in Patients With Newly Diagnosed Inflammatory Bowel Disease: Symptoms, and Clinical and Ultrasound Findings – A Population-Based Cohort Study.
- Author
-
Vladimirova, Nora, Terslev, Lene, Attauabi, Mohamed, Madsen, Gorm, Fana, Viktoria, Wiell, Charlotte, Døhn, Uffe Møller, Bendtsen, Flemming, Seidelin, Jakob, Burisch, Johan, and Østergaard, Mikkel
- Abstract
Objectives Musculoskeletal [MSK] manifestations in patients with inflammatory bowel disease [IBD] are common and associated with poorer outcomes. Hence, early detection is important to optimally tailor treatment. We aimed to determine the prevalence and distribution of inflammatory lesions in peripheral joints and entheses in newly diagnosed IBD patients. Design Patients with newly diagnosed IBD from a prospective population-based inception cohort were consecutively included. Data on MSK symptoms were collected by questionnaires and by structured rheumatological interview. Peripheral joints and entheses were assessed clinically and by ultrasound [US], using standardized definitions. Results Of 110 included patients (mean age: 42 years, 40% male, 70 with ulcerative colitis [UC], 40 with Crohn's disease [CD]), a history of ≥1 peripheral musculoskeletal symptom was reported by 49%. Clinical examination revealed peripheral MSK manifestations in 56 [52.3%] patients; 29 [27.1%] had ≥1 tender and/or swollen joints and 49 [45.8%] ≥1 tender entheses. Small peripheral joints were predominantly affected. US found inflammation in ≥1 joint or enthesis in 52 [49.5 %] patients; 29 [27.4 %] had US synovitis in ≥1 joint, while 36 [34%] had US enthesitis. Fibromyalgia classification criteria were fulfilled in seven [7.9%] patients. There was no difference in clinical or US findings between patients with UC and CD, nor between patients with active and inactive IBD. Conclusion Half of the patients with newly diagnosed IBD had inflammation in their peripheral joints and/or entheses, documented by rheumatological clinical and US evaluations. This indicates a need for multidisciplinary collaboration to ensure an optimal therapeutic strategy for suppressing inflammation in all disease domains. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Cut-Offs for Disease Activity States in Axial Spondylarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable?
- Author
-
Georgiadis, Stylianos, Ørnbjerg, Lykke Midtbøll, Michelsen, Brigitte, Kvien, Tore K., Di Giuseppe, Daniela, Wallman, Johan K., Závada, Jakub, Provan, Sella A., Kristianslund, Eirik Klami, Rodrigues, Ana Maria, Santos, Maria José, Rotar, Žiga, Pirkmajer, Katja Perdan, Nordström, Dan, Macfarlane, Gary J., Jones, Gareth T., van der Horst-Bruinsma, Irene, Hellamand, Pasoon, Østergaard, Mikkel, and Hetland, Merete Lund
- Published
- 2024
- Full Text
- View/download PDF
42. Active conventional treatment and three different biological treatments in early rheumatoid arthritis : phase IV investigator initiated, randomised, observer blinded clinical trial
- Author
-
NORD-STAR study group, Hetland, Merete Lund, Haavardsholm, Espen A, Rudin, Anna, Nordström, Dan, Nurmohamed, Michael, Gudbjornsson, Bjorn, Lampa, Jon, Hørslev-Petersen, Kim, Uhlig, Till, Grondal, Gerdur, Østergaard, Mikkel, Heiberg, Marte S, Twisk, Jos, Lend, Kristina, Krabbe, Simon, Hyldstrup, Lise Hejl, Lindqvist, Joakim, Ekwall, Anna-Karin Hultgård, Grøn, Kathrine Lederballe, Kapetanovic, Meliha, Faustini, Francesca, Tuompo, Riitta, Lorenzen, Tove, Cagnotto, Giovanni, Baecklund, Eva, Hendricks, Oliver, Vedder, Daisy, Sokka-Isler, Tuulikki, Husmark, Tomas, Ljoså, Maud-Kristine Aga, Brodin, Eli, Ellingsen, Torkell, Söderbergh, Annika, Rizk, Milad, Olsson, Åsa Reckner, Larsson, Per, Uhrenholt, Line, Just, Søren Andreas, Stevens, David John, Laurberg, Trine Bay, Bakland, Gunnstein, Olsen, Inge C, and van Vollenhoven, Ronald
- Published
- 2020
43. Atlas for the OMERACT thumb base osteoarthritis MRI scoring system (TOMS)
- Author
-
Kroon, Féline PB, Peterfy, Charles G, Conaghan, Philip G, Foltz, Violaine, Gandjbakhch, Frédérique, Eshed, Iris, Genant, Harry K, Østergaard, Mikkel, Reijnierse, Monique, Bloem, Johan L, Haugen, Ida K, and Kloppenburg, Margreet
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Arthritis ,Aging ,Osteoarthritis ,Musculoskeletal ,hand osteoarthritis ,magnetic resonance imaging ,osteoarthritis ,Clinical sciences - Abstract
This paper presents an atlas for the Outcome Measures in Rheumatology Clinical Trials (OMERACT) thumb base osteoarthritis MRI scoring system (TOMS). The atlas includes reference images of each grade of each feature that is assessed in TOMS (synovitis grade 0-3, subchondral bone defects grade 0-3, osteophytes grade 0-3, cartilage assessment grade 0-3, subluxation and bone marrow lesions grade 0-3) in the first carpometacarpal and scapho-trapezio-trapezoid joint. The presented reference images can be used to guide scoring of thumb base MRIs in patients with hand osteoarthritis according to the OMERACT TOMS.
- Published
- 2018
44. MRI-based synthetic CT: a new method for structural damage assessment in the spine in patients with axial spondyloarthritis – a comparison with low-dose CT and radiography
- Author
-
Willesen, Simone Tromborg, primary, Hadsbjerg, Anna EF, additional, Møller, Jakob Møllenbach, additional, Vladimirova, Nora, additional, Vora, Bimal M K, additional, Seven, Sengül, additional, Pedersen, Susanne Juhl, additional, and Østergaard, Mikkel, additional
- Published
- 2024
- Full Text
- View/download PDF
45. Long-term efficacy of a 2-year MRI treat-to-target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial
- Author
-
Møller-Bisgaard, Signe, primary, Hørslev-Petersen, Kim, additional, Ørnbjerg, Lykke Midtbøll, additional, Ejbjerg, Bo, additional, Hetland, Merete Lund, additional, Møller, Jakob Møllenbach, additional, Nielsen, Sabrina Mai, additional, Glinatsi, Daniel, additional, Boesen, Mikael, additional, Stengaard-Pedersen, Kristian, additional, Madsen, Ole Rintek, additional, Jensen, Bente, additional, Villadsen, Jan Alexander, additional, Hauge, Ellen Margrethe, additional, Hendricks, Oliver, additional, Lindegaard, Hanne, additional, Krogh, Niels Steen, additional, Jurik, Anne Grethe, additional, Thomsen, Henrik, additional, Christensen, Robin, additional, and Østergaard, Mikkel, additional
- Published
- 2024
- Full Text
- View/download PDF
46. Sex Differences in the Effectiveness of First‐Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network
- Author
-
Hellamand, Pasoon, primary, van de Sande, Marleen G. H., additional, Ørnbjerg, Lykke M., additional, Klausch, Thomas, additional, Eklund, Kari K., additional, Relas, Heikki, additional, Santos, Maria J., additional, Vieira‐Sousa, Elsa, additional, Loft, Anne G., additional, Glintborg, Bente, additional, Østergaard, Mikkel, additional, Lindström, Ulf, additional, Wallman, Johan K., additional, Michelsen, Brigitte, additional, Fagerli, Karen M., additional, Castrejón, Isabel, additional, Gudbjornsson, Bjorn, additional, Love, Thorvardur J., additional, Vencovský, Jiří, additional, Nekvindová, Lucie, additional, Rotar, Žiga, additional, Tomšič, Matija, additional, Díaz‐González, Federico, additional, Kenar, Gökçe, additional, Tuğsal, Handan Y., additional, Iannone, Florenzo, additional, Ramonda, Roberta, additional, Codreanu, Catalin, additional, Mogosan, Corina, additional, Nissen, Michael J., additional, Möller, Burkhard, additional, Hetland, Merete L., additional, and van der Horst‐Bruinsma, Irene E., additional
- Published
- 2024
- Full Text
- View/download PDF
47. Low incidence of malignancy in patients with suspected polymyalgia rheumatica or giant cell arteritis, examined with FDG-PET/CT
- Author
-
Gorlen, Tanja Fromberg, primary, Brittain, Jane Maestri, additional, Østergaard, Mikkel, additional, Fischer, Barbara Malene, additional, Døhn, Uffe Møller, additional, and Terslev, Lene, additional
- Published
- 2024
- Full Text
- View/download PDF
48. Validation of SPARCC MRI-RETIC e-tools for increasing scoring proficiency of MRI sacroiliac joint lesions in axial spondyloarth
- Author
-
Maksymowych, Walter, primary, Hadsbjerg, Anna Enevold Fløistrup E F, additional, Østergaard, Mikkel, additional, Micheroli, Raphael, additional, Pedersen, Susanne Juhl, additional, Ciurea, Adrian, additional, Vladimirova, Nora, additional, Nissen, Michael S, additional, Bubova, Kristyna, additional, Wichuk, Stephanie, additional, de Hooge, Manouk, additional, Mathew, Ashish J, additional, Pintaric, Karlo, additional, Gregová, Monika, additional, Snoj, Ziga, additional, Wetterslev, Marie, additional, Gorican, Karel, additional, Möller, Burkhard, additional, Eshed, Iris, additional, Paschke, Joel, additional, and Lambert, Robert GW, additional
- Published
- 2024
- Full Text
- View/download PDF
49. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
- Author
-
Ørnbjerg, Lykke M., primary, Rugbjerg, Kathrine, additional, Georgiadis, Stylianos, additional, Rasmussen, Simon H., additional, Jacobsson, Lennart, additional, Loft, Anne G., additional, Iannone, Florenzo, additional, Fagerli, Karen M., additional, Vencovsky, Jiri, additional, Santos, Maria J., additional, Möller, Burkhard, additional, Pombo-Suarez, Manuel, additional, Rotar, Ziga, additional, Gudbjornsson, Bjorn, additional, Cefle, Ayse, additional, Eklund, Kari, additional, Codreanu, Catalin, additional, Jones, Gareth, additional, van der Sande, Marleen, additional, Wallman, Johan K., additional, Sebastiani, Marco, additional, Michelsen, Brigitte, additional, Závada, Jakub, additional, Nissen, Michael J., additional, Sanchez-Piedra, Carlos, additional, Tomšič, Matija, additional, Love, Thorvardur J., additional, Relas, Heikki, additional, Mogosan, Corina, additional, Hetland, Merete L., additional, and Østergaard, Mikkel, additional
- Published
- 2024
- Full Text
- View/download PDF
50. Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
- Author
-
Michelsen, Brigitte, Georgiadis, Stylianos, Di Giuseppe, Daniela, Loft, Anne G., Nissen, Michael J., Iannone, Florenzo, Pombo‐Suarez, Manuel, Mann, Herman, Rotar, Ziga, Eklund, Kari K., Kvien, Tore K., Santos, Maria J., Gudbjornsson, Bjorn, Codreanu, Catalin, Yilmaz, Sema, Wallman, Johan K., Brahe, Cecilie H., Möller, Burkhard, Favalli, Ennio G., Sánchez‐Piedra, Carlos, Nekvindova, Lucie, Tomsic, Matija, Trokovic, Nina, Kristianslund, Eirik K., Santos, Helena, Löve, Thorvardur J., Ionescu, Ruxandra, Pehlivan, Yavuz, Jones, Gareth T., van der Horst‐Bruinsma, Irene, Ørnbjerg, Lykke M., Østergaard, Mikkel, and Hetland, Merete L.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.